Source- Merck
On June 13, 2023 the US District Court for the District of New Jersey found in favor of Merck, which is known as MSD outside of the US and Canada, and determined that Merck correctly calculated the patent term extension period for the primary patent relating to BRIDION (sugammadex). A portion of the patent life lost during the regulatory review process for new medications is intended to be recovered through patent term extension.
The US District Court for the District of New Jersey’s decision upholds and confirms Merck’s right to BRIDION’s US patent protection through at least January 2026.
“Merck’s science and technology was used to develop and launch BRIDION, and we’re pleased that the court recognized the validity of our full patent extension period granted by the Patent Office. Innovations like these contribute to a broader ecosystem that allows us to continue investing in research and development to bring important new therapies and vaccines forward to the patients who need them.”
– Jennifer Zachary, executive vice president and general counsel, Merck
